Clinical Chemistry Analyzers Market

The clinical chemistry analyzers market is projected to be valued at USD 15.92 billion in 2025 and reach USD 20.86 billion by 2030, growing at a CAGR of 5.6%. Market growth is driven by the expanding aging population and the increasing prevalence of chronic and lifestyle-related diseases, which in turn boost demand for routine biochemical testing. Simultaneously, the adoption of point-of-care testing devices is rising, reflecting a need for faster and more accessible diagnostic results. Additionally, laboratories are heavily investing in automation to manage rising test volumes and enhance operational efficiency, further promoting the adoption of advanced clinical chemistry analyzers.

In March 2025, Danaher Corporation (US) received 510(k) clearance from the US FDA for its DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. The DxC 500i offers up to 800 chemistry tests and 100 immunoassay tests per hour, combining advanced technology with an intuitive interface to deliver fast, reliable results for laboratories of all sizes.

To know about the assumptions considered for the study download the pdf brochure

In June 2024, F. Hoffmann-La Roche Ltd. (Switzerland) launched the cobas c 703 and cobas ISE neo analytical units for the cobas pro integrated solutions in CE-mark markets. The cobas c 703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling the platform’s clinical chemistry throughput. The cobas ISE neo improves ISE testing efficiency by automating maintenance and reducing hands-on time.

The key players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), Hitachi, Ltd. (Japan), EKF Diagnostics Holdings plc (UK), QuidelOrtho Corporation (US), Bruker Corporation (US), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Co., Ltd. (China), DIRUI (China), Teco Diagnostics (US), Balio diagnostics (France), Shenzhen New Industry Biomedical Engineering Co., Ltd. (China) and KPM Analytics (US).

Abbott Laboratories (US) is a leading player in the clinical chemistry analyzers market, providing a comprehensive range of analyzers to support routine and specialized diagnostic testing. The company continually invests in R&D to enhance the accuracy, efficiency, and throughput of its products, ensuring they meet the evolving needs of the laboratory. In addition, Abbott maintains a strong global presence through its network of subsidiaries and distribution channels, allowing its solutions to be accessible across hospitals, diagnostic laboratories, and other healthcare facilities in multiple regions worldwide.

F. Hoffmann-La Roche Ltd. (Switzerland) is one of the leading players in the clinical chemistry analyzer market, supported by its broad and well-established product portfolio. The company offers an extensive range of analyzers and reagents widely adopted by end users. Roche also benefits from a strong global footprint spanning North America, Europe, the Middle East, Africa, Latin America, and Asia, enabling it to serve diverse customer segments effectively. To maintain its market leadership, the company continues to prioritize new product launches as well as strategic partnerships and collaborations.

Market Ranking

Abbott (US) leads with versatile clinical chemistry systems that integrate seamlessly with its broader diagnostics portfolio, enabling labs to run a wide range of assays efficiently on unified platforms. F. Hoffmann-La Roche Ltd. (Switzerland) distinguishes itself through fully integrated testing ecosystems that combine chemistry, immunochemistry, and workflow automation, optimizing laboratory efficiency and turnaround times. Siemens Healthineers AG (Germany) focuses on high-volume, high-reliability analyzers designed for continuous operation, catering to the needs of large, centralized labs and hospital networks. Danaher Corporation (US) emphasizes scalable solutions that can adapt to varying laboratory sizes and throughput requirements, offering flexibility for growing operations. Thermo Fisher Scientific Inc. (US) serves mid-volume labs with standardized chemistry analyzers, leveraging consistent performance and extensive global distribution to support laboratories across diverse geographies.

Related Reports:

Clinical Chemistry Analyzers Market by Product [Analyzers (Fully Automated, PoC, Semi-automated), Reagents], Test Type [Lipid Profile, Liver, Basic Metabolic Panels], End User [Hospitals & Clinics, Research, Labs], Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com